Managing Secondary Hyperparathyroidism and Bone Mineral Abnormalities in Patients With CKD Stages 3-5 CME

Author Information and Disclosures

Release Date: March 26, 2008; Valid for credit through March 26, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Abbott: No Tagline
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the impact and prevalence of bone mineral abnormalities in CKD stages 3-5
  2. Review approaches to identify and treat secondary hyperparathyroidism (SHPT) and bone mineral abnormalities in patients with CKD stages 3 and 4
  3. Evaluate strategies for managing SHPT and balancing calcium and phosphate levels in patients with CKD undergoing dialysis
  4. Discuss the clinical significance of recent studies on vitamin D, calcium, and phosphate and their relation to patient survival
  5. Compare the advantages and disadvantages of active vitamin D therapy
Authors and Disclosures

Paul W. Crawford, MD
Disclosure: Paul W. Crawford, MD, has disclosed that he has served as an independent contractor to Associates in Nephrology, SC and Fresenius Medical Care, NA. Dr. Crawford has also disclosed that he has received grants for clinical research from Roche, Novo Nordisk, Fibrogen, Amgen, Johnson & Johnson, and Shire. Dr. Crawford has also disclosed that he has received grants for educational activities from Roche, Abbott, and Ortho Biotech.


Susan K. Bowes, MS
Disclosure: Susan K. Bowes, MS, has disclosed no relevant financial relationships.


Anne Le, PharmD
Disclosure: Anne Le, PharmD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.